LABORATORY AND CLINICAL STUDIES ON CS-1170

Abstract

Laboratory and clinical investigations have been carried out on CS-1170, a new semisynthetic cephamycin, and following results were obtained.
1) CS-1170 exhibited a growth inhibitory action against wide range of Gram-positive and Gram-negative bacilli, and stronger antibacterial activity than cephalothin (CET) and cephaloridine (CER) against E. coli, Klebsiella, Serratia and Proteus.
2) CS-1170 was injected intravenously by drip infusion singly as chemotherapeutic drug for respiratory tract and urinary tract infections, and favorable result was obtained in 12 cases (85.7%) out of 14 respiratory tract infections, while marked improvement was obtained in 6 cases (100%) of urinary tract infections.
3) Side effect was observed in 2 cases; eosinophilia was shown in one, and BUN elevated slightly in another with renal dysfunction.